On May 14, 2020 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported the company will receive a $15 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies (Press release, Halozyme, MAY 14, 2020, View Source [SID1234558029]). The milestone payment is associated with the first commercial sale in the United States of Janssen’s DARZALEX FASPROTM (daratumumab and hyaluronidase – fihj) utilizing ENHANZE, which was recently approved by the U.S. Food and Drug Administration.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!